Last reviewed · How we verify
Conventional Anemia Management
At a glance
| Generic name | Conventional Anemia Management |
|---|---|
| Also known as | Erythropoiesis-Stimulating Agent, Iron Supplementation |
| Sponsor | Mansoura University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pre-operative Risk Assessment Combined With Targeted Intervention in the Chinese Elderly With Spine Surgery II (NA)
- The Effect of Preoperative Intravenous Ferric Derisomaltose and EPO and Tranexamic Acid in Patients With Preoperative Anemia or Iron Deficiency in Bone Tumor (PHASE4)
- Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients (PHASE1, PHASE2)
- Perioperative Blood Conservation: Role of Combined Iron Supplementation Protocols in Reducing Allogeneic Transfusion (NA)
- Roxadustat for Bone and Neuropsychiatric Aspects in Hemodialysis Patients (PHASE1, PHASE2)
- Pentoxifylline for Vascular Calcification in Kidney Disease (PHASE1, PHASE2)
- Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia (PHASE3)
- Early Palliative Care for Patients With Haematological Malignancies (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |